Longitudinal regret after treatment for low‐ and intermediate‐risk prostate cancer

Hurwitz, Lauren M.; Cullen, Jennifer; Kim, Daniel; Elsamanoudi, Sally; Hudak, Jane; Colston, Maryellen; Travis, Judith; Kuo, Huai‐Ching; Rice, Kevin R.; Porter, Christopher R.; Rosner, Inger L.

doi:10.1002/cncr.30841

Cited by 47 publications

(45 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It consists of five items with Likert‐scale responses that were transformed into a total score of 0 to 100, with greater scores associated with higher regret 24 . Based on a validation study in prostate cancer patients, we considered a DRS score of >25 as high level of regret 24‐26 …”

Section: Methodsmentioning

confidence: 99%

Psychological distress and quality of life following positive fecal occult blood testing in colorectal cancer screening

et al. 2020

View full text Add to dashboard Cite

Objective This study aimed to assess psychological functioning, quality of life, and regret about screening after a positive fecal immunochemical test (FIT) and subsequent colonoscopy, and to evaluate changes over time. Methods This is a prospective cohort study. Individuals aged 55 to 75 with a positive FIT that were referred for colonoscopy between July 2017 and November 2018, were invited to complete questionnaires related to psychological distress and health‐related quality of life at three predefined time points: before colonoscopy, after histopathology result notification, and after 6 months. Four questionnaires were used: the Psychological Consequences Questionnaire (PCQ), the six‐item Cancer Worry Scale (CWS), the Decision Regret Scale (DRS), and the 36‐item Short‐Form (SF‐36). Results A total of 1066 participants out of 2151 eligible individuals were included. Patients with cancer showed a significant increase in psychological dysfunction (P = .01) and cancer worry (P = .008) after colonoscopy result notification, and a decline to pre‐colonoscopy measurements after 6 months. In the no‐cancer groups, psychological dysfunction and cancer worry significantly decreased over time (P < .05) but there was no ongoing decline. After 6 months, 17% of participants with no cancer experienced high level of cancer worry (CWS ≥ 10). Yet, only 5% reported high level of regret about screening participation (DRS > 25). A good global quality of life was reported in participants with no cancer. Conclusion Some psychological distress remains up to 6 months after colonoscopy in participants who tested false‐positive in the Dutch bowel cancer screening program.

show abstract

Section: Methodsmentioning

confidence: 99%

Psychological distress and quality of life following positive fecal occult blood testing in colorectal cancer screening

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Control covariates included the time since the prostate cancer diagnosis (in years) as well as binary indicators of the following: prostate cancer stage at diagnosis (T1 vs T2/T3; see Table 1), self-reported clinical diagnosis of depression before enrollment, probable depression in any prior survey wave, Charlson Comorbidity Index score (0-1 vs ≥ 2), 45 availability of social/emotional support at each survey contact, index tobacco use, index alcohol use, adherence to the exercise recommendations of the World Health Organization (WHO; ie, at least 600 metabolic equivalent minutes per week) in the 12 months preceding survey contact, 46 47,48 Treatment decisional regret was not assessed during enrollment. 49,50 This assumption was examined with sensitivity analyses. 49,50 This assumption was examined with sensitivity analyses.…”

Section: Predictorsmentioning

confidence: 99%

“…However, it was assumed that there was no regret at enrollment because 1) participants either were awaiting or had recently received cancer treatment and 2) available evidence suggests that treatment decisional regret is negligible in recently treated prostate cancer survivors. 49,50 This assumption was examined with sensitivity analyses.…”

Section: Predictorsmentioning

confidence: 99%

Prevalence and predictors of probable depression in prostate cancer survivors

Erim

Bensen

Mohler

et al. 2019

Cancer

View full text Add to dashboard Cite

Background The early diagnosis and treatment of depression are cancer care priorities. These priorities are critical for prostate cancer survivors because men rarely seek mental health care. However, little is known about the epidemiology of depression in this patient population. The goal of this study was to describe the prevalence and predictors of probable depression in prostate cancer survivors. Methods The data were from a population‐based cohort of North Carolinian prostate cancer survivors who were enrolled from 2004 to 2007 in the North Carolina–Louisiana Prostate Cancer Project (n = 1031) and were prospectively followed annually from 2008 to 2011 in the Health Care Access and Prostate Cancer Treatment in North Carolina study (n = 805). Generalized estimating equations were used to evaluate an indicator of probable depression (Short Form 12 mental composite score ≤48.9; measured at enrollment and during the annual follow‐up) as a function of individual‐level characteristics within the longitudinal data set. Results The prevalence of probable depression fell from 38% in the year of the cancer diagnosis to 20% 6 to 7 years later. Risk factors for probable depression throughout the study were African American race, unemployment, low annual income, younger age, recency of cancer diagnosis, past depression, comorbidities, treatment decisional regret, and nonadherence to exercise recommendations. Conclusions Depression is a major challenge for prostate cancer survivors, particularly in the first 5 years after the cancer diagnosis. To the authors' knowledge, this is the first study to demonstrate an association between treatment decisional regret and probable depression.

show abstract

“…Sexual dysfunction after radical prostatectomy is directly related to treatment regret, feelings of loss, and distress in relationships. [9][10][11] The importance of sexuality in prostate cancer care is evidenced by the fact that some patients are willing to sacrifice survival to preserve potency. 12 Various measures have been developed to assess symptom burden after prostate cancer treatment, including the University of California, Los Angeles Prostate Cancer Index (UCLA-PCI), 13 Expanded Prostate Index Composite-26 (EPIC-26), 14,15 and the International Index of Erectile Function (IIEF).…”

Section: Introductionmentioning

confidence: 99%

Validity of the Patient-Reported Outcome Measurement Information System (PROMIS) Sexual Interest and Satisfaction Measures in Men Following Radical Prostatectomy

Agochukwu

Wittmann

Boileau³

et al. 2019

JCO

View full text Add to dashboard Cite

PURPOSE Patient-reported outcomes after radical prostatectomy have focused on erectile function. To date, no studies have validated the Patient-Reported Outcome Measurement Information System (PROMIS) Sexual Interest and Satisfaction single item measures in patients with prostate cancer, nor have studies examined how these measures relate to erectile function. In addition, data are lacking with regard to the clinical responsiveness of these measures to treatment. We sought to validate and examine the clinical utility of these measures in men after radical prostatectomy. PATIENTS AND METHODS We identified men who underwent a robotic radical prostatectomy from May 2014 to January 2016 in the Michigan Urological Surgery Improvement Collaborative. A single item from the PROMIS Global Satisfaction With Sex Life subdomain and a single item from the PROMIS Interest in Sexual Activity subdomain were administered. Erectile function was also assessed. Differences between baseline and 24-month T-scores for both PROMIS interest and satisfaction were examined. Multilevel models were constructed to examine change over time. RESULTS A total of 1,604 patients were included in the analysis. Convergent and discriminant validity of the PROMIS measures was supported. The mean PROMIS interest T-score decreased significantly from baseline to 3 months ( P = .001) and significantly increased from 3 months to 24 months in this cohort, with 24-month scores exceeding baseline scores ( P < .001). The mean PROMIS satisfaction T-score declined from baseline to 3 months and increased from 3 months to 24 months ( P < .002). CONCLUSION PROMIS Global Satisfaction With Sex Life and Interest in Sexual Activity single-item measures are fundamental measures in prostate cancer survivorship. Patients are interested in sex despite functional losses and can salvage satisfaction, thereby giving insight into attainable patient-centered survivorship goals for sexual recovery after radical prostatectomy.

show abstract

Longitudinal regret after treatment for low‐ and intermediate‐risk prostate cancer

Abstract: In the context of a multidisciplinary clinic, decisional regret did not differ significantly between treatment groups but was greater in African Americans and those reporting poorer HRQoL. Cancer 2017;123:4252-4258. © 2017 American Cancer Society.

Cited by 47 publications

References 27 publications

Psychological distress and quality of life following positive fecal occult blood testing in colorectal cancer screening

Psychological distress and quality of life following positive fecal occult blood testing in colorectal cancer screening

Prevalence and predictors of probable depression in prostate cancer survivors

Validity of the Patient-Reported Outcome Measurement Information System (PROMIS) Sexual Interest and Satisfaction Measures in Men Following Radical Prostatectomy

Contact Info

Product

Resources

About